×

Adamas to Host Conference Call and Webcast to Provide Company Update

EMERYVILLE, Calif., April 27, 2016 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Gregory T. Went, Ph.D., Chairman and Chief Executive Officer of Adamas, will host a conference call and webcast on Thursday, April 28, at 8:00 a.m. ET/ 5:00 a.m. PT, to provide a company update.

Dial-in Information
U.S./Canada Dial-in Number: (844) 215-3280
International Dial-In Number: (484) 747-6383
Conference ID: 2778439


Interested parties may access a live audio webcast of the conference call via the Adamas Pharmaceutical website at http://ir.adamaspharma.com/events.cfm. A replay of the call will be available on the Adamas website later in the day. The replay will be available for approximately one month following the call.

About Adamas Pharmaceuticals
Adamas Pharmaceuticals, Inc. is driven to improve the lives of those affected by chronic disorders of the central nervous system. The company seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products. Adamas is currently developing ADS-5102, its lead wholly owned product candidate, for the treatment of levodopa-induced dyskinesia associated with Parkinson's disease and for the treatment of major symptoms associated with multiple sclerosis in patients with walking impairment. The company is also evaluating ADS-4101, an extended-release version of a FDA-approved single-agent compound for the treatment of epilepsy. In addition, under a license agreement with Forest Laboratories Holdings Limited, an indirect wholly owned subsidiary of Allergan plc., the company is eligible to receive royalties from Forest on sales of Namenda XR® and Namzaric™ beginning in June of 2018 and May of 2020, respectively. For more information, please visit www.adamaspharma.com.

Namzaric™ is a trademark of Merz Pharma GmbH & Co. KGaA.
Namenda XR® is a registered trademark of Merz Pharma GmbH & Co. KGaA.

For questions, please contact: Susan Lehner Corporate Communications & Investor Relations Adamas Pharmaceuticals, Inc. Phone: 510-450-3567

Source:Adamas Pharmaceuticals, Inc.